carumonam

Carumonam is a monobactam antibiotic and a small molecule drug derived from sulfazecin. It is highly resistant to beta-lactamases, making it effective against many beta-lactamase-producing Gram-negative bacteria. Carumonam acts by binding to penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting the final step of peptidoglycan synthesis, which leads to disruption of cell wall formation and ultimately bacterial cell lysis and death. Its spectrum of activity includes Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae but has limited activity against Gram-positive bacteria and anaerobes. Clinically, it has been used for urinary tract infections, respiratory tract infections, biliary tract infections, peritonitis, and sepsis[1][5][6][8]. Carumonam achieves high urinary concentrations after parenteral administration (IV or IM) and is primarily excreted via the kidneys[1][8].

Brand names

Amasulin

Other names

carumonamum